Connect your AI

Alumis Inc. ALMS Other Non-Current Assets

Other Non-Current Assets at other companies

AmgenAMGN

$12.76B+12.0%

Oruka Therapeutics, Inc.ORKA

$103K0.0%

ANI PharmaceuticalsANIP

$11.58M+12.2%

Celldex TherapeuticsCLDX

$15.43M+48.3%

ImmunomeIMNM

$5.36M+23.4%

Nektar TherapeuticsNKTR

$11.24M+108%

Other financials

Income statement

Revenue$1.7M-90.0%

Operating income-$98.4M+3.1%

Net income-$93.1M+6.0%

EPS (diluted)-$0.74+59.3%

Balance sheet

Cash & equivalents$63.9M-50.3%

Total debt$35.7M+1,881%

Total equity$567.0M+237%

Total assets$671.6M+157%

Cash flow

Operating cash flow-$87.1M-8.4%

CapEx$164.0K+343%

Free cash flow-$87.2M-8.5%

Valuation

Market cap$3.17B+739%

Profitability

Operating margin-5,364%—

Net margin-2,825.7%—

FCF margin-4,487.4%—

Returns & leverage

Return on equity-64.6%—

Debt / equity0.1×+0.1×

Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Alumis Inc.'s other non-current assets?: Alumis Inc. (ALMS) reported other non-current assets of $6.83M in Q1 2026.
How has Alumis Inc.'s other non-current assets changed year-over-year?: Alumis Inc.'s other non-current assets increased by 15080.0% year-over-year, from $45K to $6.83M.
What is the long-term trend for Alumis Inc.'s other non-current assets?: Over 2 years (2023 to 2025), Alumis Inc.'s other non-current assets has grown at a 2896.9% compound annual growth rate (CAGR), from $7K to $6.29M.
What does other non-current assets mean?: Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.